Immunogenicity poses a critical risk to all biologics, including monoclonal antibodies, ADCs, recombinant proteins, cell & gene therapies, and mRNA-based therapies. The consequences of immunogenicity can not only endanger patients but also reduce the treatment's effectiveness.
Explore how a cutting-edge, high-sensitivity in vitro immunopeptidomics assay (MHC-Associated Peptide Proteomics, or “MAPPs”) can identify regions within therapeutic proteins that are prone to HLA binding. This helps assess the sequence-based risk of activating a T cell response, which is a key factor in preclinical immunogenicity risk assessments. By integrating the MAPPs assay into your development pipeline, you can enhance lead selection, optimize candidates, and investigate known immunogenicity challenges.
This on-demand webinar:
- Presents a case study demonstrating how this assay helped identify the root cause of immunogenicity in a novel ADC that showed high levels of immunogenicity in early clinical trials.
- Explains how this advanced assay can support a more informed and proactive approach to immunogenicity risk assessment in biologics.